Skip to content

Gross margin at other companies

Indivior Pharmaceuticals, Inc.
 logo
Indivior Pharmaceuticals, Inc. INDV
81.3%+1.5pp
Viatris logo
ViatrisVTRS
34.4%-2.5pp
AMP
Amphastar PharmaceuticalsAMPH
47.3%-3.2pp
AptarGroup logo
AptarGroupATR
36.7%-1.6pp
AbbVie logo
AbbVieABBV
70.7%0.0pp
Regenxbio logo
RegenxbioRGNX
59.7%+1.0pp

Other financials

Income statement

See full
Revenue$14.4M+65.7%
Gross profit$11.0M+117%
Operating income-$4.2M+78.3%
Net income-$8.1M+64.9%
EPS (diluted)-$0.07+70.8%

Balance sheet

See full
Cash & equivalents$110.7M+61.3%
Total debt$64.4M+7.4%
Total equity-$34.1M+44.1%
Total assets$141.1M+38.0%

Cash flow

See full
Operating cash flow-$14.8M+36.7%
CapEx$52.0K-61.5%
Free cash flow-$14.9M+36.9%

Valuation

See full
Market cap$560.13M+73.5%
Enterprise value$513.76M+63.6%
P/S11.1×+5.2×

Profitability

See full
Operating margin-111.2%+96.3pp
Net margin-137.1%+80.7pp
FCF margin-88.2%-2.2pp

Returns & leverage

See full
Return on equity145.1%
Debt / equity-1.9×
Current ratio4.1×-0.8×

Where this comes from

Calculated from Aquestive Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aquestive Therapeutics, Inc.'s gross margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aquestive Therapeutics, Inc.'s gross margin?
Aquestive Therapeutics, Inc. (AQST) reported gross margin of 63.5% in Q1 2026.
How has Aquestive Therapeutics, Inc.'s gross margin changed year-over-year?
Aquestive Therapeutics, Inc.'s gross margin decreased by 7.2% year-over-year, from 68.4% to 63.5%.
What is the long-term trend for Aquestive Therapeutics, Inc.'s gross margin?
Over 4 years (2020 to 2025), Aquestive Therapeutics, Inc.'s gross margin has grown at a -5.0% compound annual growth rate (CAGR), from 71.7% to 58.3%.
What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.